Structure-activity analysis of the purine binding site of human liver glycogen phosphorylase

Chemistry and Biology

Volumn 9, Issue 8, 2002, Pages 915-924

  Ekstrom, Jennifer L ^a   Pauly, Thomas A ^a   Carty, Maynard D ^b   Soeller, Walter C ^b   Culp, Jeff ^a   Danley, Dennis E ^a   Hoover, Dennis J ^c   Treadway, Judith L ^b   Gibbs, E Michael ^b   Fletterick, Robert J ^b   Day, Yasmina S N ^d   Myszka, David G ^d   Rath, Virginia L ^a  

^a Exploratory Medicinal Sciences   (United States)

^b Department of Cardiovascular and Metabolic Diseases Biology ^*

^c PFIZER INC   (United States)

^d UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME INHIBITOR; GLYCOGEN PHOSPHORYLASE; LIGAND; PURINE DERIVATIVE; WATER;

ARTICLE; BINDING SITE; CHEMICAL STRUCTURE; CHEMISTRY; DIABETES MELLITUS; DRUG ANTAGONISM; DRUG SCREENING; ENZYMOLOGY; HUMAN; HYDROGEN BOND; INSTRUMENTATION; LIVER; METABOLISM; METHODOLOGY; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

ALLOSTERIC SITE; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; DIABETES MELLITUS; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; GLYCOGEN PHOSPHORYLASE; HUMANS; HYDROGEN BONDING; LIGANDS; LIVER; MOLECULAR STRUCTURE; PURINES; STRUCTURE-ACTIVITY RELATIONSHIP; WATER;

EID: 18544398890     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1074-5521(02)00186-2     Document Type: Article

References (31)

1. DeFronzo R.A. Pharmacologic therapy for type 2 diabetes mellitus. Ann. Int. Med. 131:1999;281-303.
2. The Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 329:1993;977-986.
3. Martin W.H., Hoover D.J., Armento S.J., Stock I.A., McPherson R.K., Danley D.E., Stevenson R.W., Barrett E.J., Treadway J.L. Discovery of a human liver glycogen phosphorylase inhibitor that lowers blood glucose in vivo. Proc. Natl. Acad. Sci. USA. 95:1998;1776-1781.
4. Fosgerau F., Westergaard N., Quistorff B., Grunnet N., Kristiansen M., Lundgren K. Kinetic and functional characterization of 1,4-dideoxy-1,4-imino-D-arabinitol. a potent inhibitor of glycogen phosphorylase with anti-hyperglyceamic effect in ob/ob mice Arch. Biochem. Biophys. 380:2000;274-284.
5. DeDecker B. Allosteric drugs. thinking outside the active-site box Chem. Biol. 7:2000;R103-R107.
6. Oikanomakos N.G., Titsanou K.E., Zographos S.E., Skamnaki V.T., Goldmann S., Bischoff H. Allosteric inhibition of glycogen phosphorylase a by the potential antidiabetic drug 3-isopropyl 4-(2-chlorophenyl)-1,4-dihydro-1-ethyl-2-methyl-pyridine-3,5,6- tricarboxylate. Protein Sci. 8:1999;1930-1945.
7. Tsitsanou K.E., Skamnaki V.T., Oikonomakos N.G. Structural basis of the synergistic inhibition of glycogen phosphorylase a by caffeine and a potential antidiabetic drug. Arch. Biochem. Biophys. 384:2000;245-254.
8. Gregoriou M., Noble M.E.M., Watson K.A., Garman E.F., Krulle T.M., De La Fuente C., Fleet G.W.J., Oikonomakos N.G., Johnson L.N. The structure of a glycogen phosphorylase glucopyranose spirohydantoin complex at 1. 8 Å resolution and 100 K. the role of the water structure and its contribution to binding Protein Sci. 7:1998;915-927.
9. Rath V.L., Ammirati M., Danley D.E., Ekstrom J.L., Gibbs E.M., Hynes T.R., Mathiowetz A.M., McPherson R.K., Olson T.V., Treadway J.L.et al. Human liver glycogen phosphorylase inhibitors bind at a new allosteric site. Chem. Biol. 7:2000;677-682.
10. Oikonomakos N.G., Skamnaki V.T., Tsitsanou K.E., Gavalas N.G., Johnson L.N. A new allosteric site in glycogen phosphorylase b as a target for drug interactions. Structure. 8:2000;575-584.
11. Myszka D.G., Morton T.A., Doyle M.L., Chaiken I.M. Kinetic analysis of a protein antigen-antibody interaction limited by mass transport on an optical biosensor. Biophys. Chem. 64:1997;127-137.
12. Kasvinsky P.J., Shechosky S., Fletterick R.J. Synergistic regulation of phosphorylase a by glucose and caffeine. J. Biol. Chem. 253:1978;9102-9106.
13. Ercan-Fang N., Nuttall F.Q. The effect of caffeine and caffeine analogs on rat liver phosphorylase a activity. J. Pharmacol. Exp. Ther. 280:1997;1312-1318.
14. Kasvinsky P.J., Madsen N.B., Sygusch J., Fletterick R.J. The regulation of glycogen phosphorylase a by nucleotide derivatives. Kinetic and X-ray crystallographic studies. J. Biol. Chem. 253:1978;3343-3351.
15. Monod J., Wyman J., Changeux J.-P. On the nature of allosteric transitions. a possible model J. Mol. Biol. 12:1965;88.
16. Engers H.D., Shechosky S., Madsen N.B. Kinetic mechanism of phosphorylase a. initial velocity studies Can. J. Biochem. 48:1970;746-754.
17. Mateo P.L., Baron C., Lopez-Mayorga O., Jimenez J.S., Cortijo M. AMP and IMP binding to glycogen phosphorylase b. J. Biol. Chem. 259:1984;9384-9389.
18. Griffiths J.R., Dwek R.A., Radda G.C.K. Conformational changes in glycogen phosphorylase studied with a spin label probe. Eur. J. Biochem. 61:1976;237-242.
19. Oikonomakos N.G., Kontou M., Zographos S.E., Watson K.A., Johnson L.N., Bichard C.J.F., Fleet G.W.J., Acharya K.R. N-acetyl-β-D-glucopyranosylamine. a potent T-state inhibitor of glycogen phosphorylase. A comparison with α-D-glucose Protein Sci. 4:1995;2469-2477.
20. Kasvinsky P.J., Madsen N.B., Fletterick R.J., Sygusch J. X-ray crystallographic and kinetic studies of oligosaccharide binding to phosphorylase. J. Biol. Chem. 253:1978;1290-1296.
21. Rath V.L., Ammirati M.L., Lemotte P.K., Fennell K.F., Mansour M.N., Danley D.E., Hynes T.R., Schulte G.K., Wasilko D.J., Pandit J. Activation of human liver glycogen phosphorylase by altering the secondary structure and packing of the catalytic core. Mol. Cell. 6:2000;1-20.
22. Oikonomakos N.G., Schnier J.B., Zographos S.E., Skamnaki V.T., Tsitsanou K.E., Johnson L.N. Flavopiridol inhibits glycogen phosphorylase by binding at the inhibitor site. J. Biol. Chem. 44:2000;34566-34573.
23. Phillips W.C. Multiple CCD detector for macromolecular X-ray crystallography. J. Appl. Crystallogr. 33:2000;243-251.
24. Otwinowski Z., Minor W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276:1997;307-326.
25. Jones T.A., Zou J.-Y., Cowan S.W., Kjeldgaard M. Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr. A. 47:1991;110-119.
26. Brunger A.T., Adams P.D., Clore G.M., DeLano W.L., Gros P., Grosse-Kunstleve R.W., Jiang J.-S., Kuszewski J., Nilges M., Pannu N.S.et al. Crystallography and NMR System; a new software suite for macromolecular structure determination. Acta Crystallogr. D54:1998;905-921.
27. van Aalten D.M.F., Bywater R., Findlay J.B.C., Hendlich M., Hooft R.W.W., Vriend G. PRODRG, a program for generating molecular topologies and unique molecular descriptors from coordinates of small molecules. J. Comput. Aided Mol. Des. 10:1996;255-262.
28. Johnsson B., Lofas S., Lindquist G. Immobilization of proteins to a carboxymethyldextran-modified gold surface for biospecific interaction analysis in surface plasmon resonance detectors. Anal. Biochem. 198:1991;268-277.
29. Myszka D.G. Improving biosensor analyis. J. Mol. Recognit. 12:1999;279-284.
30. Frostell-Karlsson A., Remaeus A., Roos A., Andersson K., Borg P., Hamalainen M., Karlsson R. Biosensor analysis of the interaction between immobilized human serum albumin and drug compounds for prediction of human serum albumin binding levels. J. Med. Chem. 43:2000;1986-1992.
31. Carson M. Ribbons 2.0. J. Appl. Crystallogr. 24:1991;958-961.